Effects of Tuberculosis and Its Treatment on Lung and Gut Microbiota: A Comprehensive Global Review and Meta-Analysis Using Amplicon-Based Metagenomics - Summary - MDSpire
Advertisement
Effects of Tuberculosis and Its Treatment on Lung and Gut Microbiota: A Comprehensive Global Review and Meta-Analysis Using Amplicon-Based Metagenomics
To examine key compositional differences between the lung and gut microbiomes of TB patients and healthy individuals, assess the consistency of microbial biomarkers across different geographic regions, and evaluate the impact of anti-TB treatment on microbiota composition.
Key Findings:
TB infection alters the diversity of lung and gut microbiota, indicating a shift in microbial balance.
Distinct compositional differences exist between the microbiomes of TB patients and healthy individuals, highlighting potential diagnostic markers.
Microbial biomarkers may show regional consistency but also exhibit geographic variation, suggesting the need for localized studies.
Anti-TB treatment significantly impacts microbiota composition, which may influence treatment outcomes.
Interpretation:
Understanding the microbiota's role in TB can inform the development of targeted interventions like prebiotics and probiotics, potentially enhancing treatment outcomes and patient care.
Limitations:
Difficulty in disentangling microbiome alterations due to TB from those caused by overlapping factors, which may confound results.
Variability in geographic, host, and methodological influences on microbiota composition, which may limit the generalizability of findings.
Conclusion:
This comprehensive review and meta-analysis provide insights into the microbiota's role in TB, highlighting the need for further research to leverage microbiome-based interventions, which could significantly improve treatment strategies.
by Monica Mbabazi, David Patrick Kateete, Faith Nakazzi, Joanitah Nabwire Wandera, Naume Mutesi, Moses Ocan, Irene Andia Biraro, Andrew Abaasa, William Evan Johnson, Bryan Wee, Adrian Muwonge
A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.
